Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462455) titled 'Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease' on March 4.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: Xiamen Amoytop Biotech Co., Ltd.

Condition: Metabolic Dysfunction-associated Steatohepatitis

Intervention: Drug: ACT500 tablets

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 31, 2026

Target Sample Size: 24

Countries of Recruitment: China

To ...